Targeting fusion oncoproteins in childhood cancers: Challenges and future opportunities for developing therapeutics
Cet article décrit les principaux enseignements tirés des principales plateformes et technologies pouvant être utilisées pour améliorer le développement de thérapies moléculaires ciblant les oncoprotéines de fusion dans les cancers pédiatriques puis présente les avancées en matière de chimie thérapeutique et de biologie chimique offrant de nouvelles perspectives de développement
Fusion oncoproteins are associated with childhood cancers and have proven challenging to target, aside from those that include kinases. As part of its efforts for targeting childhood cancers, the National Cancer Institute recently conducted a series on ‘Novel Chemical Approaches for Targeting Fusion Oncoproteins’. Key learnings on leading platforms and technologies which can be utilized to advance the development of molecular therapeutics that target fusion oncoproteins in childhood cancers are described. Recent breakthroughs in medicinal chemistry and chemical biology provide new ground and creative strategies to exploit for the development of targeted agents for improving outcomes against these recalcitrant cancers.
Journal of the National Cancer Institute , article en libre accès, 2023